Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial (Neuropsychopharmacology, 2025)

(untitled) - Chesney, E; Oliver, D; Sarma, A; Lamper, AD; Slimani, I; Lloyd, M; Dickens, AM; Welds, M; Kråkström, M; Gasparini-Andre, I; Orešič, M; Lawn, W; et al.